期刊文献+

温心汤治疗慢性心力衰竭疗效观察 被引量:4

Observation of curative effect on chronic cardiac failure with Wenxin decoction
暂未订购
导出
摘要 目的观察温心汤治疗慢性心力衰竭的临床疗效。方法将67例慢性心力衰竭患者随机分为2组,均给予西医常规治疗,治疗组同时服用温心汤,14 d为1个疗程,观察2组患者治疗前后中医证候积分、Lee氏心衰积分、NYHA心功能分级及血清醛固酮水平的变化。结果治疗组中医临床疗效总有效率为91%,对照组为82%;治疗后2组中医证候积分、血清醛固酮水平均不同程度降低,治疗组中医证候积分、血清醛固酮水平降低程度较对照组明显(P均<0.05)。治疗中未发现与试验药物有关的不良反应。结论温心汤对慢性心力衰竭有一定的临床疗效,且无明显毒副作用,其改善心功能的作用可能与其抑制过度激活的RASS系统,降低患者血清醛固酮水平有关。 Objective It is to observe the curative effects of Winxin decoction on chronic heart failure(CHD). Methods 67 patients with CHF were randomly divided into 2 groups. Both the groups were treated with normal western medicine. The treatment group was given Wenxin decoction at the same time. The treatment courses both were 14 days. The changes of traditional Chinese medical syndrome scores, Lee's CHD scores, HYHA heart function degree and the level of serum aldosterone in both groups were observed before and after treatment. Results The total effective rate of clinical traditional Chinese medical effect was 91% in treatment group and 82 % in control group. Traditional Chinese medical syndrome scores and the level of serum aldosterone in both groups were decreased more or less, but the decreasing degree in treatment group was more obviously than that in control group ( P 〈 0.05). No side effect induced by the experimental drugs was found during the treatment. Conclusion It is concluded that Wenxin decoction is effective and safe for the patients with CHF without obvious toxic and side-effect. This mechanism of improving heart function may be related to its inhibiting effect on over-activated RASS system and serum aldosterone.
出处 《现代中西医结合杂志》 CAS 2009年第25期3012-3014,共3页 Modern Journal of Integrated Traditional Chinese and Western Medicine
关键词 温心汤 慢性心力衰竭 血清醛固酮 Wenxin decoction chronic heart failure serum aldosterone
  • 相关文献

参考文献16

  • 1顾东风,黄广勇,吴锡桂,段秀芳,何江,Paul K Whelton,Stephen Mac Mahon.中国心力衰竭流行病学调查及其患病率[J].中华心血管病杂志,2003,31(1):3-6. 被引量:1297
  • 2Lenfant C. Reportof the task force on research on heart failure[J]. Circulation, 1994,90(3) : 1118 - 1123.
  • 3Diekstein K, Jaarsma T. Heart failure management programmes: delivering the message[J]. Eur J Heart Fai,2005,7:291 -293.
  • 4国家中医药管理局.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:216.
  • 5Lee DC,Johnson RA, Bingham JB, et al. Heart failure in our patients. A randomized trial of digoxin versus placebo[J]. N EngI J Med, 1982,306 : 699.
  • 6杨晋翔,邢兆宏.活血利水益气法在充血性心力衰竭中的应用[J].实用中医内科杂志,1993,7(1):1-2. 被引量:7
  • 7Baig KM, Mahon N, Mckenna WJ, et al. The pathophysioiogy of advanced heart failure[J]. Am Heart J, 1998,135(Suppl):S216- S230.
  • 8Cohn JN. Structual changes in cardiovascular disease [J].Am J Cardiol, 1995,76(15) : 34.
  • 9Cohn JN. New concepts-regarding events that lead to end-stage heart disease[J].Cardiovase Drugs Therapy, 1995,9 ( Suppl 3 ) : 489.
  • 10Cohn JN. Structual basis for heart failure ventricular remodeling and its pharmacological inhibition [J]. Circulation, 1995,91 ( 10 ) : 2504.

二级参考文献56

  • 1关继华.94例心衰气虚血瘀证的血液流变学分析[J].四川中医,1994,12(2):16-16. 被引量:5
  • 2樊宏,刘维永,晏培松,张道全.风湿性心脏病二尖瓣和心肌间质病理组织学及免疫组化观察[J].中华医学杂志,1996,76(3):183-186. 被引量:18
  • 3Delcayre C,Silvestre JS.Aldosterone and the heart:towards a physiological function?Cardiovasc Res,1999,43:7-12.
  • 4Satoh M, Nakamura M, Saitoh H, et al. Aldosterone synthase (CYP11B2)expression and myocardial fibrosis in the failing human heart. ClinSci (Lond), 2002, 102(4):381-386.
  • 5Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure--ovedoaded rats. Circulation. 2002, 106(1): 130-135.
  • 6Seeland U, Haeuseler C, Hinfichs R, et al. Myocardial fibrosis in transforming growth factor-betal (TGF-betal) transgenic mice is associated with inhibition of interstitial collagenase. Eur J Clin Invest, 2002, 32(5):295-303.
  • 7Ammarguellat F, Larouche Ⅱ, Schiffrin EL. Myocardial Fibrosis in DOCA-Salt Hypertensive Rats: Effect of Endoth ET(A) Receptor Antagonism. Circulation, 2001, 103(2):319-324.
  • 8Yang XP, Liu YH, Mehta D, et al. Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin Ⅱ type 1 receptor in B(2) kinin receptor gene knockout mice.Circ-Res, 2001, 88(10):1072-1079.
  • 9Gallagher AM, Yu RT. Bradykinin-indl,ced reductions in collagen gene expression involve prostacyclin. Hypertension, 1998, 32(2):84-88.
  • 10Yu H, Gallagher AM. Prostacyclin release by rat cardiac fibroblasts:inhibition of collagen expression. Hypertension, 1997, 30:.1047-1053.

共引文献1479

同被引文献32

  • 1钟馨.中西医结合治疗慢性阻塞性肺疾病22例[J].实用中医内科杂志,2009,23(10):75-76. 被引量:1
  • 2关继华,郝桂芳.益气活血温阳利水法治疗心衰的文献分析[J].陕西中医,1995,16(3):98-99. 被引量:21
  • 3王虎,郑维越,王继征,王晓健,甄一松,宋雷,邹玉宝,惠汝太.扩张型心肌病致病基因LMNA新突变E82K的发现及其功能的初步研究[J].中华心血管病杂志,2005,33(10):875-879. 被引量:6
  • 4王永炎,沈绍功.今日中医内科[M].上海:上海科学技术出版社,2003:523-563.
  • 5Mc Murray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 [J]. Eur J Heart Fail, 2012, 14(8): 803-869.
  • 6Hikosaka M, Yuasa F, Yuyama R, and arterial barore-flexsen sitivity nerve activity inpatients with mild Cardiovasc Pharmacol, 2002, 40(6) et al. Candesart an and sympat hetic heart failure [J]. J : 875-880.
  • 7Kavita Radhakrishnan, Cynthia Jacelon. Impact of telehealth on patient self-management of heart failure~ a review of literature[J]. J Cardiovasc Nurs, 2012, 27 (1): 33-43.
  • 8Fonarow GC,Stough WG, Abraham WT, et al. Characteristics, treatments,and outcomes of patients with preserved systolic function hospitalized for heart failure:a report from the OPTIMIZE-HF Registry.[J].Am Coll Crdiol,2007,50 (7):768- 777.
  • 9关继华.中医治疗心力衰竭的研究进展[C].第一届全国中青年中医学术研讨会,1994,北京.
  • 10关继华.心力衰竭的中医分型探讨[C].首届中医国际心病学术研讨会,1992,北京.

引证文献4

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部